Ovarian reserve, oxidative stress and glycemic profile parameters in women with type 1 diabetes mellitus using different insulin therapy regimens

BACKGROUND: Women with type 1 diabetes mellitus (DM) have a high frequency of menstrual irregularities and perinatal complications. New methods for monitoring the glycemic profile provide opportunities to analyze the effectiveness of insulin therapy regimens in maintaining the reproductive health of these patients.

AIM: The aim of the study was to assess the relationship between glycemic profile patterns, pro- and antioxidant statuses, and ovarian reserve parameters in type 1 DM patients.

MATERIALS AND METHODS: This study included 60 type 1 DM women, of whom 30 patients aged 33.0 [30.0; 35.0] years used the multiple insulin injections (MII) regimen (Group 1). In this group, patients were divided into two subgroups: not exceeding the percentage of hyperglycemia above the target range for more than 35% of the day (Group 1A) and exceeding this range (Group 1B). The continuous subcutaneous insulin infusion (CSII) regimen was administered to other 30 patients (Group 2). They were subdivided identically into Groups 2A and 2B. We analyzed continuous glucose monitoring data using the FreeStyle Libre Flash Glucose Monitoring System and evaluated blood malonic dialdehyde level, catalase activity and 3-nitrotyrosine level, as well as ovarian volume, antral follicle count, anti-Müllerian hormone and follicle-stimulating hormone levels.

RESULTS: We found no differences in the time in range in Groups 1A and 2A. The HbA1c level was higher in the time above range group of women using MII. Blood 3-nitrotyrosine level in Group 1B was 161.4 [110.6; 232.1] nmol/l and differed from that in Group 2B (42.4 [19.1; 64.9] nmol/l; p<0.01). A relationship was found between catalase activity and soluble receptor for advanced glycation end-products (sRAGE) levels in Group 2A (rs=0.857; p<0.05). The antral follicle count tended to increase when the target range of glucose levels was exceeded above 7.8 mmol/l for more than 35% of the day.

CONCLUSION: Preliminary data were obtained on the relationship between hyperglycemia exceeding 7.8 mmol/l for more than 35% of the day with oxidative stress parameters, sRAGE levels, and a tendency towards an increase in the antral follicle count in women with type 1 DM.

1. Healthdata.org [internet]. Global Burden of Disease Collaborative Network. Global Burden of Disease Study 2019. Results. Institute for Health Metrics and Evaluation. 2020 [cited 2024 Sept 16]. Available from: https://vizhub.healthdata.org/gbd-results/

2. Zaimi M, Michalopoulou O, Stefanaki K, et al. Gonadal dysfunction in women with diabetes mellitus. Endocrine. 2024;85(2):461-472. doi: https://doi.org/10.1007/s12020-024-03729-z

3. Misharina EV, Yarmolinskaya MI, Tiselko AV. Type 1 diabetes mellitus; ovarian reserve; anti-Müllerian hormone; ovarian function. J Obst Women’s Dis. 2024; 73(4):31-42. (In Russ.) doi: https://doi.org/10.17816/JOWD631790

4. Misharina EV, Osinovskaya NS, Yarmolinskaya MI. The role of polymorphic variants of the kisspeptin gene in the pathogenesis of ovarian insufficiency in patients with type 1 diabetes mellitus, genital endometriosis and combination of these diseases. J Obst Women’s Dis. 2023;72:25-36. (In Russ.) doi: https://doi.org/10.17816/JOWD346690

5. Gaete X, Vivanco M, Eyzaguirre FC, et al. Menstrual cycle irregularities and their relationship with HbA1c and insulin dose in adolescents with type 1 diabetes mellitus. Fertil Steril. 2010;94(5):1822-1826. doi: https://doi.org/10.1016/j.fertnstert.2009.08.039

6. Farrar D, Tuffnell DJ, West J, West HM. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev. 2016;2016(6):CD005542. doi: https://doi.org/10.1002/14651858.CD005542.pub3

7. Escobar-Morreale HF, Roldán-Martín MB. Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis. Diabetes Care. 2016;39(4):639-648. doi: https://doi.org/10.2337/dc15-2577

8. Šoupal J, Škrha J Jr, Fajmon M, et al. Glycemic variability is higher in type 1 diabetes patients with microvascular complications irrespective of glycemic control. Diabetes Technol Ther. 2014;16(4):198-203. doi: https://doi.org/10.1089/dia.2013.0205

9. Yan LJ. Redox imbalance stress in diabetes mellitus: Role of the polyol pathway. Animal Model Exp Med. 2018;1(1):7-13. doi: https://doi.org/10.1002/ame2.12001

10. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603. doi: https://doi.org/10.2337/dci19-0028

11. Keyu G, Jiaqi L, Liyin Z, et al. Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis. Front Public Health. 2022;10:990281. doi: https://doi.org/10.3389/fpubh.2022.990281

12. Rimon MTI, Hasan MW, Hassan MF, Cesmeci S. Advancements in Insulin Pumps: A Comprehensive Exploration of Insulin Pump Systems, Technologies, and Future Directions. Pharmaceutics. 2024;16(7):944. doi: https://doi.org/10.3390/pharmaceutics16070944

13. Tiselko AV, Misharina EV, Yarmolinskaya MI, et al. Evaluation of folliculogenesis and oxidative stress parameters in type 1 diabetes mellitus women with different glycemic profiles. Endocrine. 2024;85(3):1131-1140. doi: https://doi.org/10.1007/s12020-024-03805-4

14. Dedov II, Shestakova MV, Mayorov AY, et al. Standards of Specialized Diabetes Care / Edited by Dedov II, Shestakova MV, Mayorov AYu. 11th Edition. Diabetes mellitus. 2023;26(2S):1-157. (In Russ.) doi: https://doi.org/10.14341/DM13042

15. Laffel LM, Kanapka LG, Beck RW, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2020;323(23):2388-2396. doi: https://doi.org/10.1001/jama.2020.6940

16. Miller KM, Bauza C, Kanapka LG, et al. Continuous Glucose Monitoring Provides Durable Glycemic Benefit in Adolescents and Young Adults with Type 1 Diabetes: 12-Month Follow-Up Results. Pediatr Diabetes. 2023;2023:6718115. doi: https://doi.org/10.1155/2023/6718115

17. Kim C, Dunn RL, Braffett B, et al. Ovarian reserve in women with Type 1 diabetes in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study. Diabet Med. 2016;33(5):691-692. doi: https://doi.org/10.1111/dme.13072

18. Mochizuki M, Kikuchi T, Urakami T, et al. Improvement in glycemic control through changes in insulin regimens: findings from a Japanese cohort of children and adolescents with type 1 diabetes. Pediatr Diabetes. 2017;18(6):435-442. doi: https://doi.org/10.1111/pedi.12409

19. Chen Q, Liu L, Ke W, et al. Association between the soluble receptor for advanced glycation end products and diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord. 2024;24(1):232. doi: https://doi.org/10.1186/s12902-024-01759-2

20. Prasad K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int J Angiol. 2014;23(1):11-16. doi: https://doi.org/10.1055/s-0033-1363423

21. Lam JK, Wang Y, Shiu SW, et al. Effect of insulin on the soluble receptor for advanced glycation end products (RAGE). Diabet Med. 2013;30(6):702-709. doi: https://doi.org/10.1111/dme.12166

22. Zhou Z, Sun B, Huang S, et al. Glycemic variability: adverse clinical outcomes and how to improve it?. Cardiovasc Diabetol. 2020;19(1):102. doi: https://doi.org/10.1186/s12933-020-01085-6

23. Klimontov VV. Glycemic variability in diabetes mellitus / Klimontov VV, Myakina NE. - 2nd edition, revised and supplemented. - Novosibirsk: Novosibirsk National Research State University, 2018. (In Russ.)